Compare DexCom, Inc. (DXCM) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Remitly Global Inc — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Remitly Global Inc trades at $25.6 (market cap $5.26B). The key difference: DexCom, Inc. is far larger — about 5.3× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | RELY | |
|---|---|---|
Market Cap | $28.06B | $5.26B |
Sector | Health | Technology |
52-Week High | $89.53 | $24.96 |
52-Week Low | $54.84 | $12.20 |
Enterprise Value | $27.03B | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
RELY stock trades at $25.57, up 8.72% in the last 24 hours, showing strong momentum. The company demonstrates accelerating revenue growth from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. Technical indicators show bullish momentum with the current price near resistance at $26. Recent expansion into UAE and Canadian markets positions the company for continued international growth.
RELY presents a compelling growth story with improving profitability and strong analyst support (92% buy ratings). However, elevated valuation multiples (P/E 52) and competitive pressures in the remittance space warrant caution. The stock's upside potential to the $27.40 consensus target appears reasonable given accelerating revenue and expanding margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
